Last reviewed · How we verify
DICL-SR — Competitive Intelligence Brief
marketed
NSAID (nonsteroidal anti-inflammatory drug)
COX-1 and COX-2
Rheumatology / Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
DICL-SR (DICL-SR) — Kunming Baker Norton Pharmaceutical Sales Co., Ltd.. DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DICL-SR TARGET | DICL-SR | Kunming Baker Norton Pharmaceutical Sales Co., Ltd. | marketed | NSAID (nonsteroidal anti-inflammatory drug) | COX-1 and COX-2 | |
| Cytotec | Misoprostol | Pfizer | marketed | NSAID combined with prostaglandin analog | Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors | 1988-01-01 |
| Metamizole Sodium | Metamizole Sodium | Insel Gruppe AG, University Hospital Bern | marketed | Non-steroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | |
| High Dose Ibuprofen | High Dose Ibuprofen | Ottawa Hospital Research Institute | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | COX-1 and COX-2 | |
| Loxoprofen sodium hydrogel patch | Loxoprofen sodium hydrogel patch | Sun Yat-sen University | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | |
| ACULAR | ACULAR | University of South Alabama | marketed | NSAID (nonsteroidal anti-inflammatory drug) | COX-1 and COX-2 | |
| Surgery with Naproxen | Surgery with Naproxen | Giovana Maria Weckwerth | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)
- Depomed · 1 drug in this class
- Dong-A ST Co., Ltd. · 1 drug in this class
- Handok Inc. · 1 drug in this class
- Imprimis Pharmaceuticals, Inc. · 1 drug in this class
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
- LEO Pharma · 1 drug in this class
- Novartis · 1 drug in this class
- Pfizer · 1 drug in this class
- University of South Alabama · 1 drug in this class
- ZARS Pharma Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DICL-SR CI watch — RSS
- DICL-SR CI watch — Atom
- DICL-SR CI watch — JSON
- DICL-SR alone — RSS
- Whole NSAID (nonsteroidal anti-inflammatory drug) class — RSS
Cite this brief
Drug Landscape (2026). DICL-SR — Competitive Intelligence Brief. https://druglandscape.com/ci/dicl-sr. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing